Deregulation of SOCS5 suppresses dendritic cell function in chronic lymphocytic leukemia

DSpace/Manakin Repository

Deregulation of SOCS5 suppresses dendritic cell function in chronic lymphocytic leukemia

Citable link to this page

 

 
Title: Deregulation of SOCS5 suppresses dendritic cell function in chronic lymphocytic leukemia
Author: Toniolo, Patricia A.; Liu, Suhu; Yeh, Jennifer E.; Ye, Darwin Q.; Barbuto, José Alexandre M.; Frank, David A.

Note: Order does not necessarily reflect citation order of authors.

Citation: Toniolo, Patricia A., Suhu Liu, Jennifer E. Yeh, Darwin Q. Ye, José Alexandre M. Barbuto, and David A. Frank. 2016. “Deregulation of SOCS5 suppresses dendritic cell function in chronic lymphocytic leukemia.” Oncotarget 7 (29): 46301-46314. doi:10.18632/oncotarget.10093. http://dx.doi.org/10.18632/oncotarget.10093.
Full Text & Related Files:
Abstract: One cause of morbidity and mortality in chronic lymphocytic leukemia (CLL) is infection, which results from defects in a number of components of the immune system. In particular, dendritic cells (DCs) are functionally defective in patients with CLL. To understand the molecular mechanism for this abnormality, we focused on signal transduction pathways that regulate the function of monocyte-derived dendritic cells (Mo-DCs). Monocytes from CLL patients exhibit high IL-4Rα expression due to the enhanced activation of STAT3. However, IL-4R signaling is decoupled from activation of its downstream mediator STAT6 by enhanced levels of the negative regulator SOCS5. This impairs differentiation of functionally mature DCs leading to decreased expression of HLA-DR and costimulatory molecules, and reduced secretion of pro-inflammatory cytokines in LPS-activated DCs. Moreover, Mo-DCs from CLL patients display a decreased ability to induce pro-inflammatory T-cell responses. IL-10-treatment of monocytes from healthy donors mimics the alteration in signaling observed in CLL patients, through enhanced STAT3-dependent expression of SOCS5. The higher level of SOCS5 inhibits STAT6 activation and leads to defective DC differentiation. These findings indicate that SOCS5 mediates the impaired function of DCs in CLL patients, and has the potential to be a new therapeutic target for reversing cancer-associated immune suppression.
Published Version: doi:10.18632/oncotarget.10093
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216799/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:30370950
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters